These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 37835573)

  • 1. Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.
    Das K; Paul S; Ghosh A; Gupta S; Mukherjee T; Shankar P; Sharma A; Keshava S; Chauhan SC; Kashyap VK; Parashar D
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.
    Khadela A; Soni S; Megha K; Shah AC; Pandya AJ; Kothari N; Shah I; Avinash CB
    Med Oncol; 2022 Dec; 40(1):48. PubMed ID: 36520261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer.
    St-Denis-Bissonnette F; Khoury R; Mediratta K; El-Sahli S; Wang L; Lavoie JR
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
    Graham R; Gazinska P; Zhang B; Khiabany A; Sinha S; Alaguthurai T; Flores-Borja F; Vicencio J; Beuron F; Roxanis I; Matkowski R; Liam-Or R; Tutt A; Ng T; Al-Jamal KT; Zhou Y; Irshad S
    Front Immunol; 2023; 14():1204224. PubMed ID: 37441083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting triple negative breast cancer stem cells using nanocarriers.
    Dasari N; Guntuku GS; Pindiprolu SKSS
    Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development.
    Subbarayan R; Srinivasan D; Balakrishnan R; Kumar A; Usmani SS; Srivastava N
    Int Rev Cell Mol Biol; 2024; 389():104-152. PubMed ID: 39396845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of exosomes in the treatment of triple-negative breast cancer.
    Weaver JW; Zhang J; Rojas J; Musich PR; Yao Z; Jiang Y
    Front Mol Biosci; 2022; 9():1022725. PubMed ID: 36438660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Vesicles: The Landscape in the Progression, Diagnosis, and Treatment of Triple-Negative Breast Cancer.
    Dong M; Liu Q; Xu Y; Zhang Q
    Front Cell Dev Biol; 2022; 10():842898. PubMed ID: 35300426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
    Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
    Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.
    Llinàs-Arias P; Íñiguez-Muñoz S; McCann K; Voorwerk L; Orozco JIJ; Ensenyat-Mendez M; Sesé B; DiNome ML; Marzese DM
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
    Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
    Front Oncol; 2021; 11():648139. PubMed ID: 34094935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer.
    Shettigar A; Salunke R; Modi D; Mukherjee N
    Int Immunopharmacol; 2023 Jun; 119():110250. PubMed ID: 37163922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.